Effects of efpeglenatide versus liraglutide on gastric emptying, glucose metabolism and beta-cell function in people with type 2 diabetes: an exploratory, randomized phase Ib study.

Hompesch M, Kang J, Han O, Trautmann ME, Sorli CH, Ogbaa I, Stewart J, Morrow L

BMJ open diabetes research & care1 Jun 2021Cited by 14 (Europe PMC)

PMID34172436PMCIDPMC8237726DOI10.1136/bmjdrc-2021-002208PepBankPUB-34172436

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In people with T2D, weekly efpeglenatide was non-inferior to liraglutide for delaying gastric emptying at peak drug concentrations.
In plain wordsIn people with diabetes, weekly efpeglenatide was non-inferior to liraglutide for slowing stomach emptying at peak drug concentrations.
Peptide
Efpeglenatide
Outcome
Not applicableGastric emptying delay
Study
n: not reported in source
Comparator
Liraglutide 1.8 mg daily
Analysis
Exploratory
Outcome group
Gastrointestinal motility · Gastrointestinal
Studied dose
6 mg weekly · approximately 1 monthAs given in this study (human).
Source sentences
Summary
At peak drug concentrations, efpeglenatide 6 mg QW was non-inferior to liraglutide 1.8 mg QD in delaying gastric emptying, as assessed by acetaminophen PK (lower bound of 90% CI for the efpeglenatide:liraglutide ratio >0.8 for area under the curve (AUC)_0-120, AUC_0-180, AUC…
5 context sentences(design, population, supporting numbers)
Summary · context
Treatment duration was approximately 3 months for efpeglenatide 16 mg QM and 1 month for efpeglenatide 6 mg QW and liraglutide.
Summary · context
To evaluate the effects of efpeglenatide, a long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA), on gastric emptying, glucose metabolism, and islet beta-cell function versus liraglutide and placebo in people with type 2 diabetes.
Summary · context
This phase Ib study (ClinicalTrials.gov identifier: NCT02059564) randomized participants (n=47) to three cohorts.
Summary · context
Within the first two cohorts, participants were randomized to placebo, efpeglenatide 6 mg weekly (QW; first cohort), or efpeglenatide 16 mg monthly (QM; second cohort).
Summary · context
The third cohort received liraglutide 1.8 mg daily (QD).
Report a problemFND-3417243604
02HumanRandomized controlled trialEfficacy outcome
In people with T2D, monthly efpeglenatide delayed gastric emptying less than liraglutide, and non-inferiority was not shown.
In plain wordsIn people with diabetes, monthly efpeglenatide slowed stomach emptying less than liraglutide.
Peptide
Efpeglenatide
Outcome
DecreaseGastric emptying delay
Study
n: not reported in source
Comparator
Liraglutide 1.8 mg daily
Analysis
Exploratory
Outcome group
Gastrointestinal motility · Gastrointestinal
Studied dose
16 mg monthly · approximately 3 monthsAs given in this study (human).
Source sentences
Summary
Efpeglenatide 16 mg QM did not decrease the rate of gastric emptying to as great an extent as liraglutide (ie, non-inferiority was not shown).
5 context sentences(design, population, supporting numbers)
Summary · context
Treatment duration was approximately 3 months for efpeglenatide 16 mg QM and 1 month for efpeglenatide 6 mg QW and liraglutide.
Summary · context
To evaluate the effects of efpeglenatide, a long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA), on gastric emptying, glucose metabolism, and islet beta-cell function versus liraglutide and placebo in people with type 2 diabetes.
Summary · context
This phase Ib study (ClinicalTrials.gov identifier: NCT02059564) randomized participants (n=47) to three cohorts.
Summary · context
Within the first two cohorts, participants were randomized to placebo, efpeglenatide 6 mg weekly (QW; first cohort), or efpeglenatide 16 mg monthly (QM; second cohort).
Summary · context
The third cohort received liraglutide 1.8 mg daily (QD).
Report a problemFND-3417243605
03HumanRandomized controlled trialEfficacy outcome
In people with T2D, both efpeglenatide regimens (6 mg weekly and 16 mg monthly) showed comparable or more favorable glucometabolic effects than liraglutide.
In plain wordsIn people with type 2 diabetes, both efpeglenatide schedules had blood sugar effects comparable to or better than liraglutide.
Peptide
Efpeglenatide
Outcome
Not applicableGlucometabolic effects
Study
n: not reported in source
Comparator
Liraglutide 1.8 mg daily
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
6 mg weekly or 16 mg monthly · approximately 1 month (6 mg weekly) or approximately 3 months (16 mg monthly)As given in this study (human).
Source sentences
Summary
Compared with liraglutide, both efpeglenatide dosing regimens demonstrated comparable or more favorable glucometabolic effects and improved beta-cell function.
5 context sentences(design, population, supporting numbers)
Summary · context
Treatment duration was approximately 3 months for efpeglenatide 16 mg QM and 1 month for efpeglenatide 6 mg QW and liraglutide.
Summary · context
To evaluate the effects of efpeglenatide, a long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA), on gastric emptying, glucose metabolism, and islet beta-cell function versus liraglutide and placebo in people with type 2 diabetes.
Summary · context
This phase Ib study (ClinicalTrials.gov identifier: NCT02059564) randomized participants (n=47) to three cohorts.
Summary · context
Within the first two cohorts, participants were randomized to placebo, efpeglenatide 6 mg weekly (QW; first cohort), or efpeglenatide 16 mg monthly (QM; second cohort).
Summary · context
The third cohort received liraglutide 1.8 mg daily (QD).
Report a problemFND-3417243606
04HumanRandomized controlled trialEfficacy outcome
In people with T2D, both efpeglenatide regimens (6 mg weekly and 16 mg monthly) demonstrated improved beta-cell function in the comparison with liraglutide.
In plain wordsIn people with type 2 diabetes, both efpeglenatide schedules were reported to improve beta-cell function in the comparison with liraglutide.
Peptide
Efpeglenatide
Outcome
IncreaseBeta-cell function
Study
n: not reported in source
Comparator
Liraglutide 1.8 mg daily
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
6 mg weekly or 16 mg monthly · approximately 1 month (6 mg weekly) or approximately 3 months (16 mg monthly)As given in this study (human).
Source sentences
Summary
Compared with liraglutide, both efpeglenatide dosing regimens demonstrated comparable or more favorable glucometabolic effects and improved beta-cell function.
5 context sentences(design, population, supporting numbers)
Summary · context
Treatment duration was approximately 3 months for efpeglenatide 16 mg QM and 1 month for efpeglenatide 6 mg QW and liraglutide.
Summary · context
To evaluate the effects of efpeglenatide, a long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA), on gastric emptying, glucose metabolism, and islet beta-cell function versus liraglutide and placebo in people with type 2 diabetes.
Summary · context
This phase Ib study (ClinicalTrials.gov identifier: NCT02059564) randomized participants (n=47) to three cohorts.
Summary · context
Within the first two cohorts, participants were randomized to placebo, efpeglenatide 6 mg weekly (QW; first cohort), or efpeglenatide 16 mg monthly (QM; second cohort).
Summary · context
The third cohort received liraglutide 1.8 mg daily (QD).
Report a problemFND-3417243608
05HumanRandomized controlled trialSafety outcome
In people with T2D, all gastrointestinal adverse events with efpeglenatide were mild or moderate and transient during treatment and follow-up.
In plain wordsIn people with diabetes, all digestive adverse events with efpeglenatide were mild or moderate and temporary.
Peptide
Efpeglenatide
Outcome
Not applicableGastrointestinal adverse event severity and course
Study
n: not reported in source
Analysis
Exploratory
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
All gastrointestinal adverse events reported with efpeglenatide were mild or moderate in severity and transient over treatment and follow-up.
4 context sentences(design, population, supporting numbers)
Summary · context
To evaluate the effects of efpeglenatide, a long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA), on gastric emptying, glucose metabolism, and islet beta-cell function versus liraglutide and placebo in people with type 2 diabetes.
Summary · context
This phase Ib study (ClinicalTrials.gov identifier: NCT02059564) randomized participants (n=47) to three cohorts.
Summary · context
Within the first two cohorts, participants were randomized to placebo, efpeglenatide 6 mg weekly (QW; first cohort), or efpeglenatide 16 mg monthly (QM; second cohort).
Summary · context
The third cohort received liraglutide 1.8 mg daily (QD).
Report a problemFND-3417243610
06HumanRandomized controlled trialEfficacy outcome
In people with type 2 diabetes, efpeglenatide 6 mg weekly was non-inferior to liraglutide 1.8 mg daily in delaying gastric emptying, so the delay was comparable.
In plain wordsIn people with type 2 diabetes, liraglutide and weekly efpeglenatide slowed stomach emptying to a comparable degree.
Peptide
Liraglutide
Outcome
No significant changeGastric emptying delay versus efpeglenatide 6 mg weekly
Study
n: not reported in source
Comparator
Efpeglenatide
Outcome group
Gastrointestinal function · Gastrointestinal
Studied dose
1.8 mg daily · 1 monthAs given in this study (human).
Source sentences
Summary
At peak drug concentrations, efpeglenatide 6 mg QW was non-inferior to liraglutide 1.8 mg QD in delaying gastric emptying
1 context sentence(design, population, supporting numbers)
Summary · context
The third cohort received liraglutide 1.8 mg daily (QD).
Report a problemFND-3417243601
07HumanRandomized controlled trialEfficacy outcome
In people with type 2 diabetes, liraglutide 1.8 mg daily slowed gastric emptying more than efpeglenatide 16 mg monthly, which did not show non-inferiority.
In plain wordsIn people with type 2 diabetes, liraglutide slowed stomach emptying more than monthly efpeglenatide.
Peptide
Liraglutide
Outcome
IncreaseGastric emptying delay versus efpeglenatide 16 mg monthly
Study
n: not reported in source
Comparator
Efpeglenatide
Outcome group
Gastrointestinal function · Gastrointestinal
Studied dose
1.8 mg daily · 1 monthAs given in this study (human).
Source sentences
Summary
Efpeglenatide 16 mg QM did not decrease the rate of gastric emptying to as great an extent as liraglutide (ie, non-inferiority was not shown).
1 context sentence(design, population, supporting numbers)
Summary · context
The third cohort received liraglutide 1.8 mg daily (QD).
Report a problemFND-3417243602
08HumanRandomized controlled trialEfficacy outcome
In people with type 2 diabetes, both efpeglenatide regimens had glucometabolic effects comparable to or more favorable than liraglutide, with improved beta-cell function.
In plain wordsIn people with type 2 diabetes, both efpeglenatide doses were comparable to or better than liraglutide for blood sugar control and beta-cell function.
Peptide
Liraglutide
Outcome
MixedGlucometabolic effects and beta-cell function versus efpeglenatide
Study
n: not reported in source
Comparator
Efpeglenatide
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg daily · 1 monthAs given in this study (human).
Source sentences
Summary
Compared with liraglutide, both efpeglenatide dosing regimens demonstrated comparable or more favorable glucometabolic effects and improved beta-cell function.
1 context sentence(design, population, supporting numbers)
Summary · context
The third cohort received liraglutide 1.8 mg daily (QD).
Report a problemFND-3417243603

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 1NCT02059564

A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

Hanmi Pharmaceutical Company Limitedn = 44Dec 2013 to est. Dec 2014

Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 11 Feb 2014

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 4 to 7Current
28 Oct 2026, 02:03 UTC
The same notice was added 4 times, first on 27 Oct 2026, 18:20 UTC. The status did not change between them.
Study results updated
Version 3
27 Oct 2026, 16:32 UTC
Study data updated · source update from Europe PMC
Version 2
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Effects of efpeglenatide versus liraglutide on gastric emptying, glucose metabolism and beta-cell function in people with type 2 diabetes: an exploratory, randomized phase Ib study.

Summary

Results from this study8

Registered trials1

A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

Version history

Subjects

Publication types

MeSH terms

Keywords